VPCO is making real money, with trailing revs already coming in at $8.89M.
•VPCO is coming off an RSI trough under 25 on the weekly chart, pointing to a massively oversold stock now heading back the other way.
•VPCO just recorded a MACD Bullish reversal, suggesting a technical change in trend.
Vape Industry Blows Away Tobacco Industry – Courtesy, US Finance Post
The electronic cigarette business is booming, thanks to a court decision and no government regulation. The boom in the vape industry, as it is commonly called, is leading to a decline in traditional cigarette smokers, according to statistics.
The vape boom since 2013 is credited to a number of factors. One primary reason is that restrictions on traditional smokers increased with fewer places available to them for their habit. Health insurance companies are also encouraging people to kick the habit with incentives for non-smokers and heavy penalties to those who do smoke.
Landowners, who have had vacant buildings since the economic downturn are offering deals to those who want to open vape stores and more potential business owners are eyeing the vape industry as a successful way to be entrepreneurs.
Numbers from 2013 show there are 3,500 vape stores in the United States, with more than a dozen stores opening up in some cities every year. The expansion took a sharp upward turn after a 2009 U.S. Food and Drug Administration (FDA) decision was overturned by a federal court in 2010. The FDA wanted more regulations on the e-cigarette industry. Current regulations apply only to those e-cigarettes listed as a therapeutic device, and not those listed as standard for sale for pleasure devices.
VPCO is positioned for success. And the chart says that success looks likely to be immediate. There’s no time to lose with this one!
Too much competition, China economy will recover in 5 years, watch all banks forecast sales (LOWER) due to china. S& P needs to test new low
Preparation for Regulatory Agency Meetings and Initiation of Partnering discussions:
Preparation is underway for planned regulatory agency meetings early next year, where Propanc management is expected to meet with the Federal Institute for Drugs and Medical Devices in Germany (BfArM), European Medicines Agency (EMA) and US Food and Drug Administration (FDA). The scientific advice meetings will be an opportunity to discuss key activities planned for the future development of PRP, including animal safety/ toxicology studies and the proposed clinical pathway for human studies in Phase I and II.